New Launch23 Oct 2025, 03:33 pm
Cipla and Lilly Sign Marketing and Distribution Agreement for Second Brand of Tirzepatide in India
AI Summary
Cipla Ltd. and Eli Lilly and Company (India) Pvt. Ltd. have entered into a marketing and distribution agreement for the launch of a second brand of Tirzepatide in India under the brand name Yurpeak™. Tirzepatide is a prescription based, dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated for the treatment of type 2 diabetes and chronic weight management in adults. The product will be launched upon receipt of regulatory approvals. This agreement aims to expand the availability of tirzepatide, enabling broader access across India.
Key Highlights
- Cipla and Lilly sign a marketing and distribution agreement for a second brand of Tirzepatide in India.
- Tirzepatide is a dual agonist of GIP and GLP-1 receptors, indicated for the treatment of type 2 diabetes and chronic weight management.
- The second brand of Tirzepatide will be launched under the name Yurpeak™.
- The product will be launched upon receipt of regulatory approvals.
- This agreement aims to expand the availability of tirzepatide, enabling broader access across India.